Teva joins Watson Health in R&D link-up

Credit: Teva

Teva has partnered with the IBM Watson Health Cloud to create a global technology platform to aid its R&D efforts in asthma, pain, migraine and neurodegenerative diseases.

The Israeli firm will work with IBM on long-range platform and solutions development, with experts collaborating to enhance IBM Watson Health Cloud capabilities and explore synergies with existing Watson Health ecosystem partners.

Teva says it expects to develop solutions designed to collect and analyse real world evidence, draw powerful insights and inform a variety of initiatives such as reducing drug misuse or increasing prescribed medication adherence.

In addition, a joint Teva-IBM Research team will deploy big data and machine learning technology to create disease models and advanced therapeutic solutions.

Guy Hadari, senior vice president and chief information officer for Teva Pharmaceutical Industries says: "Teva is actively exploring the e-health evolution with a strong focus on fulfilling unmet and emerging patients' needs. The IBM Watson Health Cloud provides a strong foundation on which we can realise this vision."

"By building on the Watson Health Cloud, we believe Teva will be in a unique position to put the best information and insights in the hands of physicians, care teams and patients, to empower treatment optimisation for individuals and populations across the spectrum of acute and chronic conditions. Watson holds promise to provide Teva with better insights, real-time feedback and options for clinicians to consider to improve patient care."

Watson is a cognitive computing platform that represents a new era of computing based on its ability to interact in natural language, process vast amounts of big data to uncover patterns and insights, and learn from each interaction. The Watson Health Cloud provides an open development platform for physicians, researchers, insurers and companies focused on creating health and wellness solutions.

Yasmita Kumar